Aeroflow Health, a health tech company, has expanded its lactation consultation services to Virginia Medicaid, it announced Thursday. Asheville, North Carolina-based Aeroflow Health was founded in 2001 and offers an array of medical devices covered by insurance. The company has four lines: Aeroflow Breastpumps, Aeroflow Diabetes, Aeroflow Sleep and Aeroflow Urology. In addition to medical devices, it provides education and consultations. The company has partnerships with more than 1,000 insurance plans. Through Aeroflow’s partnership with Virginia Medicaid and its managed care organizations, new mothers can access breast pumps from Aeroflow. They will also be connected to Aeroflow’s network of lactation consultants. Members can receive one-on-one lactation consultations and online courses that cover topics like breastfeeding, pumping and storing breastmilk. “This partnership between Aeroflow Health and Virginia Medicaid broadens access to lactation services from Aeroflow Breastpumps for new and expecting mothers,” Amanda Minimi, director of corporate development at Aeroflow Health, told ...
Why can some people easily stop eating when they are full and others can’t, which can lead to obesity? A Northwestern Medicine study has found one reason may be a newly discovered structural connection between two regions in the brain that appears to be involved in regulating feeding behavior. These regions involve the sense of smell and behavior motivation. The weaker the connection between these two brain regions, the higher a person’s Body Mass Index (BMI), the Northwestern scientists report. The investigators discovered this connection between the olfactory tubercle, an olfactory cortical region, which is part of the brain’s reward system, and a midbrain region called the periaqueductal gray (PAG), involved in motivated behavior in response to negative feelings like pain and threat and potentially in suppression of eating. The study will be published May 16 in the Journal of Neuroscience. Previous research at Northwestern by co-author Thorsten Kahnt, now ...
Mike Hollan The platform will use AI technology to provide pharmacists with more tools. The relationship between the pharma industry, pharmacists, and customers continues to evolve. EmpiRx Health, a PBM company headquartered in NJ, announced that it is launching a new AI-powered platform.1 The new platform is called Clinically, and it will use AI technology to help pharmacists with claims adjudication, clinical reviews, and other features that EmpiRx says will put the pharmacists at the center of the PBM model. In a press release, EmpiRx’s CEO Danny Sanchez said, “Our new Clinically platform clearly demonstrates EmpiRx Health’s strong commitment to transforming the pharmacy care industry by creating the PBM of the future – one that’s already providing the highest quality service to customers, patients, and advisor partners. This PBM revolution was long overdue. Far from helping plan sponsors to manage and lower drug costs, the traditional PBM model, which prioritizes ...
Ultrasound imaging serves as a noninvasive method to locate and monitor cancerous tumors effectively. However, crucial details about the cancer, such as the specific types of cells and genetic mutations involved, typically require invasive biopsies, which can cause harm. Now, a research team has developed a new method to utilize ultrasound for gently extracting this genetic information. Researchers at the University of Alberta (Edmonton, AB, Canada) have been investigating the use of intense ultrasound in releasing biological indicators of disease, or biomarkers, from cells. These biomarkers include elements like miRNA, mRNA, DNA, and various genetic mutations, all of which are critical for identifying the cancer type and guiding treatment decisions. The ultrasound technique releases these biomarkers from the cells into the bloodstream, where they reach concentrations high enough to be detected. This enables oncologists to identify and track the cancer’s status or response to treatment through blood samples instead of ...
The condition is the ninth most common cancer in the UK and affects 12,300 people annually The National Institute for Health and Care Research (NIHR) and the Tessa Jowell Brain Cancer Mission (TJBCM) have announced a new innovative package of research funding to stimulate brain tumour research in adults, children and young people. The announcement emerges from a collaboration between charities, research funders and the government, which pledged £40m to develop new lifesaving and life-improving research. Currently the ninth most common cancer in the UK, affecting around 12,300 people every year, according to the Brain Tumour Charity, brain tumours occur when a growth of cells in the brain multiplies in an abnormal, uncontrollable way. In 2018, members of the brain tumour community united to design a national strategy and the government committed funding for new research, following the late Dame Tessa Jowell’s call to action on behalf of brain tumour ...
Organiser:Messe Düsseldorf Time:21- 23 August 2024 address:No. 688 East Suzhou Avenue, Suzhou Industrial Park, Suzhou City Exhibition hall: Suzhou International Expo Centre, China Product range: Hospital facilities and equipment: Medical electronic instruments, ultrasound instruments, X-ray equipment, medical optical instruments, clinical examination and analysis instruments, dental equipment and materials, hemodialysis equipment, anesthesia and respiratory equipment, disposable medical supplies, dressings and hygiene materials, all kinds of surgical instruments Hospital wards, operating rooms, emergency room equipment, hospital office equipment, laboratory equipment, beds, operating tables, operating table spotlights, inspection Check the bed, gums and all kinds of hospital furniture Medical care equipment: all kinds of medical and home rehabilitation physiotherapy products About CDMEE: Jiangsu Suzhou Medical Device Innovation Exhibition (Medical Fair China) with the theme of “smart health”, directly and comprehensively serving the medical device industry from the source to the terminal of the entire medical industry chain. Gather advanced medical technology products at ...
Engineers from the Massachusetts Institute of Technology (MIT) have developed a new technique using magnetic resonance imaging (MRI) to detect light deep in the brain, which could benefit future studies of the development and communication of brain cells. Published in Nature Biomedical Engineering, the new technique could help researchers explore the inner workings of the brain, such as changes in gene expression, anatomical connections between cells or how cells communicate with each other. Commonly, scientists label cells with bioluminescent proteins that glow to allow them to track the growth of a tumour or measure changes in gene expression that occur as cells differentiate. Known as bioluminescence, the novel technique uses MRI to observe the dilation of a protein in the brain’s blood vessels to pinpoint the source of light. The team came up with a method to transform the blood vessels of the brain into light detectors to find a ...
Don Tracy, Associate Editor Dupixent has previously been approved for adults with chronic rhinosinusitis with nasal polyposis whose condition is inadequately controlled. Regeneron and Sanofi announced that the FDA has granted Priority Review to their supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment for adolescents aged 12 to 17 years who have chronic rhinosinusitis with nasal polyposis (CRSwNP) and whose condition is inadequately controlled. With the treatment already approved for adults with CRSwNP, the FDA is expected to make a final decision on the sBLA for the expanded indication by September 15, 2024.1 According to the companies, the application is supported by efficacy data from SINUS-24 and SINUS-52, two trials that showed major improvements in nasal congestion/obstruction severity, nasal polyp size, sense of smell, and a reduction in the need for systemic corticosteroids or surgery. In 2019, Regeneron first released the results of both trials, ...
For the second month in a row, the NHS has met the 28-day faster diagnosis target for cancer The NHS has announced, for the second month in a row, that it has met the 28-day faster diagnosis target for cancer as well as faster ambulance responses to call outs compared to March 2024. The announcement builds on targeted national support for NHS trusts in reducing variation across the country and speeding up diagnosis for patients, while also bringing down the backlog of patients waiting for diagnosis or treatment from the COVID-19 pandemic. New published data has shown that the number of patients waiting more than 62 days for care is now at its lowest ever since the end of April 2020, reducing by almost 20,000 patients since the post-pandemic peak. In addition, almost 77% of people referred or screened received a definitive diagnosis or were all clear within four weeks, ...
The sandbox will help to inform future AI Airlock projects and influence future AlaMD guidance The Medicines and Healthcare products Regulatory Agency (MHRA) has launched AI Airlock, a new regulatory sandbox, to address the challenges of regulating medical devices that use artificial intelligence (AI). In alignment with the regulator’s goal for the UK to be a science and technology superpower by 2030, the new sandbox builds on the MHRA’s strategic approach to AI in April, which was set out to respond to a white paper published by the government in 2023. It highlighted that the regulator is considering the opportunities and risks of AI from three perspectives: as a regulator of AI products, as a public service organisation delivering time-critical decisions and as an organisation that produces evidence-based decisions that impact public and patient safety, where evidence is often supplied by third parties. The new sandbox for AI as a ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.